{"id":"W4245051009","doi":"10.2165/00128413-200514740-00048","title":"Health Canada has approved bortezomib [Velcade; Millennium Pharmaceuticals].","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Bortezomib; Pharmacy; Pharmacology; Family medicine; Oncology; Internal medicine; Multiple myeloma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005963845,0.0004137706,0.0006252468,0.0007116595,0.00187221,0.001401094,0.001037553,0.00174792,0.05219409],"category_scores_gemma":[0.001780837,0.000216632,0.0006119373,0.000772335,0.0006926133,0.000318488,0.0005072257,0.002230473,0.01008633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006963014,"about_ca_system_score_gemma":0.030184,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4806408,"about_ca_topic_score_gemma":0.7510665,"domain_scores_codex":[0.998991,0.00008320557,0.00002797588,0.00006306633,0.0006248821,0.0002099548],"domain_scores_gemma":[0.998522,0.0001332532,0.00008074963,0.00003669855,0.000687696,0.0005397098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007841016,0.0004006803,0.0042897,0.0005191188,0.00005664126,0.000612342,0.00009500963,0.0001877493,0.00603332,0.003505711,0.7164144,0.2671013],"study_design_scores_gemma":[0.0002692869,0.000210165,0.004375981,0.0001527745,0.00004863531,0.0005299872,0.00009951188,0.0002129951,0.00286532,0.0003552302,0.9908575,0.00002265457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.03330292,0.06575408,0.003852539,0.1133072,0.006734433,0.00089591,0.009918763,0.002954009,0.7632802],"genre_scores_gemma":[0.2031607,0.03950015,0.009336101,0.04014246,0.0009547689,0.0001888419,0.009532009,0.0004321167,0.6967529],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.5193592,"threshold_uncertainty_score":0.9556863,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2246281412208943,"score_gpt":0.51268809366099,"score_spread":0.2880599524400956,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}